Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax plus zanubrutinib versus placebo plus zanubrutinib in relapsed/refractory mantle cell lymphoma
2024-515593-27-00Phase 3Authorised
- Sponsor
- BeOne Medicines
- Start
- May 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in mantle cell lymphoma (MCL) comparing Sonrotoclax plus zanubrutinib with Placebo plus zanubrutinib (2 arms). Primary endpoint: Progression-free survival. Planned start May 2025; status: authorised.
02
Drugs
sonrotoclaxzanubrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2024-515593-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515593-27-00.